Lucentis (Ranibizumab)

Ranibizumab is a medicine used to treat a specific type of vision loss called wet age-related macular degeneration. It works by blocking a protein called VEGF, which helps leaky blood vessels in the eye. This helps to stop the vision loss.

Brand names:Lucentis
Medication

What people taking Lucentis (Ranibizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lucentis (Ranibizumab) for Wet Macular Degeneration?

NameHow it went

About Lucentis (Ranibizumab)

What It's For

Ranibizumab, sold as Lucentis, is a prescription medicine injected into the eye to treat conditions in which abnormal or leaky blood vessels threaten central vision. It is approved for wet age-related macular degeneration (wet AMD), in which fragile new vessels grow beneath the retina and leak fluid or blood. It also treats macular edema, a swelling of the macula (the part of the retina responsible for sharp central vision), when it follows a retinal vein occlusion, a blockage in one of the retina's veins. Its other approved uses are diabetic macular edema and diabetic retinopathy, the eye damage caused by diabetes, and myopic choroidal neovascularization, abnormal vessel growth that can develop in severely nearsighted eyes. Ranibizumab belongs to a group of eye treatments called anti-VEGF medicines, which also includes aflibercept (Eylea) and bevacizumab (Avastin), a cancer medicine that eye specialists also use off-label. Biosimilar versions, which the FDA approved as highly similar to Lucentis, are sold as Byooviz and Cimerli, and not every version is approved for every use. Susvimo is a different ranibizumab product: a concentrated form delivered by a small refillable implant surgically placed in the eye. It is meant for people with wet AMD, diabetic macular edema or diabetic retinopathy who have already responded to at least two anti-VEGF injections.

How It Works

VEGF (vascular endothelial growth factor) is a protein that stimulates new blood vessel growth and makes vessel walls leakier. In wet AMD and the other conditions ranibizumab treats, VEGF activity in the eye drives the growth of fragile vessels and the seepage of fluid into the retina. That fluid blurs and distorts central vision, and over time bleeding and scarring can destroy the cells that make it possible. Ranibizumab is a fragment of a laboratory-made antibody that latches onto VEGF and keeps it from reaching its receptors on vessel walls. With less VEGF signaling, leakage slows, swelling in the retina goes down and new vessel growth is held back. The effect fades as the drug is cleared, which is why treatment has to be repeated. Ranibizumab controls these conditions rather than curing them, and it cannot bring back retinal cells that have already been lost to scarring.

Dosage & Administration

Ranibizumab is given only by an eye specialist, usually a retina specialist, as an injection into the vitreous, the clear gel that fills the back of the eye. The eye is numbed and cleaned beforehand to lower the chance of infection. Most people feel pressure rather than sharp pain, and the injection itself takes only moments. The doctor checks the eye, including its internal pressure, before you leave. Plan for someone else to drive you home. The labeled schedule for Lucentis is one injection a month. In wet AMD, injections are often spaced out after the first few months based on vision checks and scans; the label notes that less frequent dosing is somewhat less effective, on average, than staying on monthly injections. For macular edema after a vein occlusion, the label recommends continuing monthly injections, because people who paused after six months lost some vision on average. Myopic choroidal neovascularization often needs fewer injections, starting with up to three monthly doses and retreatment only when needed. Diabetic macular edema and diabetic retinopathy are treated with a lower-strength dose. The Susvimo implant releases the drug continuously and is refilled in the clinic about every six months for wet AMD and diabetic macular edema, or about every nine months for diabetic retinopathy. If you miss an appointment, call the clinic as soon as possible to reschedule.

Side Effects

Most side effects come from the injection itself. A small patch of blood on the white of the eye at the injection site is the most common. Eye soreness, a gritty feeling, new floaters (small specks drifting across vision) and a rise in eye pressure are also common, and some people notice dry, itchy or watery eyes or briefly blurred vision. The serious risks are an infection inside the eye, called endophthalmitis, along with retinal detachment and inflammation of the retina's blood vessels. Serious problems linked to the injection procedure occur in fewer than 1 in 1,000 injections, but they can threaten sight and respond best to early treatment. In the days after an injection, contact your eye doctor right away, the same day, if the eye becomes increasingly red or painful, sensitive to light, or your vision gets worse or cloudier, or if you notice flashing lights or a sudden increase in floaters or specks. With a Susvimo implant, these same signs need a same-day call at any time, not only after a refill.

Interactions & Warnings

Ranibizumab is not given while there is an infection in or around the eye, or to anyone who has had an allergic reaction to it; in the eye, such a reaction can show up as severe inflammation. Tell your eye doctor before each visit about any eye infection, inflammation or new eye problem. The label notes a possible risk of stroke and heart attack with anti-VEGF medicines injected into the eye. In the trials these events were uncommon; in wet AMD their rates were low and not clearly higher than in the comparison groups, and in vein occlusion they were similar. In two diabetic eye disease trials, deaths were somewhat more frequent with monthly ranibizumab than with a sham (placebo) treatment, and strokes were more frequent at a higher dose than the one now used for diabetic eye disease. Most deaths had causes typical of advanced diabetes, and the label says a link cannot be ruled out. Tell your doctor if you have had a heart attack or stroke so the benefits and risks can be weighed together. Because blocking VEGF could affect a developing baby, ranibizumab is used in pregnancy only when clearly needed. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding. Formal drug interaction studies have not been done, so your eye team should still have your full list of medicines and supplements. When ranibizumab was combined with photodynamic therapy, an older light-activated treatment for wet AMD, serious eye inflammation was reported in about 1 in 10 people, mostly when the injection was given about a week after it. The Susvimo implant carries an FDA boxed warning, the agency's most prominent caution: it has been linked to up to three times the rate of eye infection seen with monthly injections, many of them tied to the tissue over the implant pulling back or wearing thin. People with the implant need that area checked regularly so problems can be repaired early, and the infection warning signs under Side Effects apply for as long as the implant is in place.

What to Expect

Ranibizumab is mainly a way to protect the vision you still have, and for some people it also improves it. In the original wet AMD trials, about 95% of people given monthly injections kept their vision after a year (meaning they lost fewer than three lines on an eye chart), and roughly a third gained three lines or more. Eyes given a sham treatment lost about two lines on average over the same year. Some people notice clearer or less distorted vision within the first few months; others mainly hold steady, which is still a meaningful result for a condition that otherwise tends to worsen. Treatment is usually long term. At follow-up visits the specialist checks vision and often takes an OCT scan (optical coherence tomography, a quick, painless image of the retina's layers) to see whether fluid has returned, and uses the results to decide whether to inject and when to schedule the next visit. Stretching the interval too far or stopping can let leakage return and vision slip, so keeping appointments matters. If the response is incomplete, the specialist may adjust the schedule or discuss other anti-VEGF medicines. In wet AMD, bevacizumab gave similar vision results when given on the same schedule, and biosimilar versions of ranibizumab have performed about the same as Lucentis, so cost and insurance coverage often shape which medicine is used.

Questions to Ask Your Doctor

  1. 1.Why are you recommending ranibizumab rather than another anti-VEGF medicine or a biosimilar, and how do the costs compare under my insurance?
  2. 2.How often will I need injections at first, and how will we decide whether to space them out?
  3. 3.Which symptoms after an injection should make me call you the same day, and how do I reach you after hours?
  4. 4.Does my history of heart disease, stroke or diabetes change the risks of this treatment for me?
  5. 5.What vision results are realistic for my condition, and how will we judge whether the treatment is working?

Last reviewed • Oct 2026

Educational content, not medical advice.